Cognition in The Blood (Biomarker) How do digital cognitive assessments relate to the Blood Plasma p-Tau217 in patients with Mild Cognitive Impairment (MCI)? Our latest research explores an exciting dataset with the AI–Mind Project, who have given us the opportunity to test the associations of our cognitive assessments alongside classic paper-and-pencil tests to levels of […]

The post Cognition in The Blood (Biomarker) appeared first on Cambridge Cognition.

Cambridge Cognition launches Speaker Identification Solution to Safeguard Clinical Trial Integrity 12 August 2025 Cambridge Cognition Holdings plc (AIM:COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to announce the commercial launch of a proprietary speaker identification solution developed to tackle duplicate participant enrolment […]

The post Cambridge Cognition launches Speaker Identification Solution to Safeguard Clinical Trial Integrity   appeared first on Cambridge Cognition.

Trading update for period ended 30 June 2025 31st July 2025 Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, announces a trading update for the six months ended 30 June 2025. Highlights ·    New Sales Orders of £6.9m (H1 2024: £3.3m) ·    Order Book of £16.4m (30 […]

The post Trading update for period ended 30 June 2025 appeared first on Cambridge Cognition.

There is no excerpt because this is a protected post.

The post Protected: Integrating Blood-Based Biomarkers & Digital Cognitive Assessments to Accelerate Brain Health Research appeared first on Cambridge Cognition.

AAIC25 | Posters & Presentations Toronto, Canada | 27th – 31st July | Booth 1531 Unveiling Cutting-Edge Alzheimer’s & Dementia Research at AAIC 2025: A Sneak Peek at Our Latest Posters The Alzheimer’s Association International Conference (AAIC) is just around the corner, and we’re incredibly excited to share some of the latest research our team […]

The post AAIC25 | Posters & Presentations appeared first on Cambridge Cognition.

Cambridge Cognition Investment, Monument Therapeutics, Achieves Positive Phase I Results for Novel Schizophrenia Treatment 23rd June 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to report that Monument Therapeutics, in which the Group has a 20% holding, has achieved […]

The post Cambridge Cognition Investment, Monument Therapeutics, Achieves Positive Phase I Results for Novel Schizophrenia Treatment appeared first on Cambridge Cognition.

SIRS 2025: Insights on Schizophrenia Research, From Rights Based Care to Digital Biomarkers Michael Spilka, Sr. Clinical Scientist This year’s Schizophrenia International Research Society (SIRS) 2025 Congress in Chicago brought together leading scientists and researchers, exploring the latest advancements and ongoing challenges in understanding and addressing schizophrenia. Michael Spilka, PhD. shares his key insights from […]

The post SIRS 2025: Insights on Schizophrenia Research, From Rights Based Care to Digital Biomarkers appeared first on Cambridge Cognition.

Spin-out Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board Thursday 17th April Manchester, UK, 17 April 2024 – Monument Therapeutics, a precision, neuroscience company focused on the development of innovative treatments forserious central nervous system disorders (CNS), today announced two key leadership appointments. Robert S. Radie (Bob) has […]

The post Monument Therapeutics Announces Appointment of Robert Radie as Chair and Heather Preston to Advisory Board appeared first on Cambridge Cognition.

Dementias Platform UK: TRANSLATION 2025 Martina De Lillo, Clinical Scientist We recently attended TRANSLATION 2025, organized by Dementia Platform UK, where experts shared groundbreaking developments in treatment approaches, diagnostic methods, and research methodologies. The presentations revealed a field undergoing rapid transformation, with significant implications for patients and healthcare professionals alike. The theme of the conference […]

The post Dementias Platform UK: TRANSLATIONS 2025 appeared first on Cambridge Cognition.

When to Use Standardised Assessments—And When You Might Need to Build Your Own Alex Kaula, Senior R&D Scientist Hello, I’m Alex Kaula, Senior R&D Scientist at Cambridge Cognition. If your research involves measuring cognitive function or clinical outcomes, you’ve likely faced this question: Should I use an established, validated assessment, or create a new one […]

The post When to Use Standardised Assessments—And When You Might Need to Build Your Own appeared first on Cambridge Cognition.

Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial 10 April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical […]

The post Cambridge Cognition Secures £1million Contract for Phase 3 Autoimmune Disease Trial appeared first on Cambridge Cognition.

Cambridge Cognition selected for two Phase 3 Trials combining digital cognitive and voice solutions 3rd April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase […]

The post Cambridge Cognition selected for two Phase 3 trials combining digital cognitive and voice solutions  appeared first on Cambridge Cognition.

Cambridge Cognition selected for two Phase 3 Trials combining digital cognitive and voice solutions 3rd April 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has been selected by a major pharmaceutical company to provide digital cognitive and voice assessments for two Phase […]

The post Cambridge Cognition selected for two Phase 3 trials combining digital cognitive and voice solutions  appeared first on Cambridge Cognition.

SIRS 2025 | Posters & Presentations Chicago, IL. USA | 29th March – 2nd April 2025 Be the first to gain access to new data and insights, presented at SIRS 2025. Access Posters Sunday 30th March 12:00-14:00 S162 – Identification of Robust Speech-Based Markers of Negative Symptom Severity in Schizophrenia Spectrum Disorders, by Michael Spilka […]

The post SIRS 2025 | Posters & Presentations appeared first on Cambridge Cognition.

AD/PD 2025 | Posters & Presentations Vienna, Austria | 1st-5th April 2025 Be the first to gain access to new data and insights, presented at AD/PD 2025. Access Posters This year at AD/PD, we can’t wait to share our latest research with you with poster presentations from Emily Thorp, Francesca Cormack and Nick Taptiklis.  2nd-3rd […]

The post AD/PD 2025 | Posters & Presentations appeared first on Cambridge Cognition.

Actigraphy and wearable sensor technologies to enhance assessment in health conditions affecting motor function and behaviour Reflections from the 2025 Actigraph Digital Data Summit​ The 2025 @Actigraph Digital Data Summit in Pensacola, FL, provided a valuable environment for exploring the potential and challenges of using actigraphy, and other wearable sensor technologies, to enhance assessment in […]

The post Actigraphy and wearable sensor technologies to enhance assessment in health conditions appeared first on Cambridge Cognition.

CANTAB® demonstrates substantial value in one of the largest brain health studies ever conducted 6 March 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, announces its involvement in one of the world’s largest brain health studies, the Intuition Brain Health study1, demonstrating […]

The post CANTAB® demonstrates substantial value in one of the largest brain health studies ever conducted  appeared first on Cambridge Cognition.

Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment 25 February 2025 Manchester, 25th February 2025 — Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel investors. The investment will be used […]

The post Monument Therapeutics secures £850k to advance breakthrough schizophrenia treatment appeared first on Cambridge Cognition.

Cambridge Cognition submits FDA Letter of Intent for Cognitive Impairment Assessments in Schizophrenia 18 February 2025 Cambridge Cognition (AIM: COG), the brain health software group specialising in digital products to advance clinical research and patient treatment, has submitted a Letter of Intent to the U.S. Food and Drug Administration (FDA) under the Drug Development Tool […]

The post Cambridge Cognition submits FDA Letter of Intent for Cognitive Impairment Assessments in Schizophrenia appeared first on Cambridge Cognition.

ISCTM | 21st Annual Scientific Meeting Washington, D.C., USA | 19-21 February 2025 About the ISCTM The International Society for CNS Clinical Trials and Methodology (ISCTM) is an independent multi-disciplinary organization devoted to promoting advances in, and dissemination of, clinical research methods related to development and use of CNS therapeutics. The ISCTM accomplishes this by […]

The post ISCTM 2025 appeared first on Cambridge Cognition.